Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of GBS
3.2.1.2 Growing awareness for rare disease treatment
3.2.1.3 Government supporting policies and funding
3.2.1.4 Expanding R&D investment
3.2.1.5 Advancements in diagnostics and treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects of treatments
3.2.2.2 Regulatory and reimbursement challenges
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Competitive analysis of major market players
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 First-line treatment
5.2.1 Intravenous immunoglobulin (IVIG)
5.2.2 Plasma exchange (Plasmapheresis)
5.3 Supportive treatment
Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Acute inflammatory demyelinating polyneuropathy (AIDP)
6.3 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
6.4 Miller fisher syndrome (MFS)
6.5 Acute motor axonal neuropathy (AMAN)
6.6 Other types
Chapter 7 Market Estimates and Forecast, By Gender, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Male
7.3 Female
Chapter 8 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Below 20 years
8.3 21-40 years
8.4 41-59 years
8.5 60 and above
Chapter 9 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospitals
9.3 Clinics
9.4 Rehabilitation centers
9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 Biogen Inc.
11.3 Cadila Healthcare Limited
11.4 CSL Behring LLC
11.5 F.Hoffmann-La Roche Ltd.
11.6 GSK plc
11.7 Grifols SA
11.8 LGM Pharmaceuticals, Inc.
11.9 Merck & Co., Inc.
11.10 Octapharma AG
11.11 Pfizer Inc.
11.12 Takeda Pharmaceutical Company Limited
